Letters to the Editor

We appreciate Dr Liner's interest in our paper. We agree, as we stated in the paper, that lincomycin is not a first line drug and should be reserved for the patient population described in his letter.¹ Furthermore, we certainly concur that the incidence of pseudomembranous colitis (PMC) following parenteral lincomycin is lese than 2%, in fact much less. If indeed the true incidence is 2%, then the probability of observing one or more cases of PMC in our series of 265 is 0.995, and thus the probability of observing no cases is 0.005.